ProStrakan pushing to break even in 2009
Scotland-based speciality pharmaceuticals group ProStrakan has posted its financials for 2007 which show that revenues rose 19% while its losses were reduced dramatically.
Read MoreAuthor: Kevin Grogan
Bayer buys Sagmel’s OTC portfolio to boost Russian expansion
Just under a fortnight after telling PharmaTimes World News that it was looking to boost its consumer health operations, Bayer has swooped to buy the over-the-counter assets of the USA’s Sagmel.
Read MorePromising data for GSK’s Cervarix and Merck & Co’s Gardasil
GlaxoSmithKline and Merck & Co have been extolling the virtues of their respective cervical cancer vaccines as the battle for market share starts to heat up.
Read MoreMannkind will keep flying the flag for inhaled insulin
The USA’s MannKind Corp says it is determined to push ahead with its investigational inhaled insulin product, despite Eli Lilly becoming the latest firm to decide that such treatments have little commercial value.
Read MoreGSK at centre of a moral storm over disclosure of data
GlaxoSmithKline may have escaped the threat of prosecution after being accused of delaying the submission of safety data concerning the antidepressant Seroxat but the firm’s reputation, and indeed that of the whole industry, is under scrutiny again.
Read More- GSK wins US approval for ROS1 lung cancer therapy
- Lundbeck secures FDA Fast Track for narcolepsy drug
- R1 Therapeutics begins global phase 2b trial of AP306 for hyperphosphatemia
- Mission Therapeutics divests MTX652 to Dimerix in deal worth up to $292 million
- Nouscom to present re‑treatment data in Lynch Syndrome at ESMO 2026
